Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focusing on neurodegenerative diseases, announced participation in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 1:00 p.m. ET. This event is exclusive to BTIG clients. Yumanity is advancing innovative therapies, with its lead candidate, YTX-7739, in Phase 1 for Parkinson’s disease. The company aims to overcome misfolded protein toxicity through its drug discovery platform, targeting conditions such as Lewy body dementia, ALS, FTLD, and Alzheimer’s.
- None.
- None.
BOSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021, at 1:00 p.m. ET.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.
Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006
Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
rflamm@burnsmc.com / hwong@burnsmc.com
(212) 213-0006 ext. 364 / 316
FAQ
What is Yumanity Therapeutics' main focus?
When is Yumanity Therapeutics participating in the BTIG Virtual Biotechnology Conference?
What is the lead product candidate of Yumanity Therapeutics?
What other neurodegenerative diseases are targeted by Yumanity Therapeutics?
